DHR on NYSE

Danaher Corporation

Logo: KarimKoueider, Public domain, via Wikimedia Commons6

American healthcare company

Danaher Corporation is an American healthcare company headquartered in Washington, D.C. It develops products used for advances in biotechnology, life sciences, and diagnostics.3 It was founded by Mitchell Rales and Steven Rales.1 Its revenue was $31.5 billion in 2022.1 Its shares trade on NYSE under the symbol DHR.1 Wikipedia text CC BY-SA 4.0

$228.73 down 2.77 (1.20%)Price as of Oct 16, 2026 at 19:58 UTC

Last updated Oct 21, 2026.

Overview

1981Founded1

Compare with Roper Technologies, Ametek or Keysight Technologies, or pick any stock.

  • TickerDHR on NYSE1
  • Industryconglomerate1
  • HeadquartersWashington, D.C.1
  • Websitewww.danaher.com
  • Legal formDelaware corporation1
  • Incorporated inDE7
  • Business address2200 Pennsylvania Ave. N.W., Suite 800W, Washington, Dc 20037-17017
  • Filer categoryLarge accelerated filer7
  • LEIS4BKK9OTCEWQ3YHPFM114
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 21035944

Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology (28% of 2024 revenues), which develops products for the development of therapeutics; life sciences (31% of 2024 revenues), which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics (41% of 2024 revenues), which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

59.1%Gross margin10
19.1%Operating margin10
14.7%Net margin10
2.9%Revenue growth, 202510
6.9%Return on equity10
0.35×Debt to equity10
$5.3BFree cash flow10

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Revenue from Contract with Customer, Measurement, Recurring brought in 82% of the revenue Danaher Corporation broke down this way in fiscal 2025.

  1. Revenue from Contract with Customer, Measurement, Recurring$20.1B1082%up 4% from 2024
  2. Revenue from Contract with Customer, Measurement, Nonrecurring$4.4B1018%down 2% from 2024
Products and services by year
Products and services202320242025
Revenue from Contract with Customer, Measurement, Recurring$18.7B$19.4B$20.1B
Revenue from Contract with Customer, Measurement, Nonrecurring$5.2B$4.5B$4.4B

Business segments

Diagnostics brought in 40% of the revenue Danaher Corporation broke down this way in fiscal 2025.

  1. Diagnostics$9.9B1040%up 2% from 2024
  2. Life Sciences$7.3B1030%up 0% from 2024
  3. Biotechnology$7.3B1030%up 8% from 2024
Business segments by year
Business segments202320242025
Diagnostics$9.6B$9.8B$9.9B
Life Sciences$7.1B$7.3B$7.3B
Biotechnology$7.2B$6.8B$7.3B

Regions

North America brought in 42% of the revenue Danaher Corporation broke down this way in fiscal 2025.

  1. North America$10.4B1042%up 1% from 2024
  2. High-Growth Markets$7.0B1029%up 2% from 2024
  3. Western Europe$5.9B1024%up 9% from 2024
  4. Other Developed Markets$1.3B105%down 0% from 2024
Regions by year
Regions202320242025
North America$10.0B$10.3B$10.4B
High-Growth Markets$7.2B$6.9B$7.0B
Western Europe$5.5B$5.5B$5.9B
Other Developed Markets$1.3B$1.3B$1.3B

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue41¢$10.0B
  • Research and development7¢$1.6B
  • Selling, general and admin34¢$8.2B
  • Other costs2¢$443.0M
  • Income tax3¢$633.0M
  • Profit15¢$3.6B

Out of $24.6B in revenue.10

Where each dollar of operating cash went, fiscal 2025

  • Capital spending18¢$1.2B
  • Dividends paid14¢$878.0M
  • Share buybacks48¢$3.1B
  • Kept or used elsewhere20¢$1.3B

Out of $6.4B of cash from operations.10

Financial statements

Revenue1112131410$24.6B in 2025+37% since 2019
0$10.0B$20.0B$30.0B2019: $17.9B$17.9B20192020: $22.3B$22.3B2020+24%2021: $24.8B$24.8B2021+11%2022: $26.6B$26.6B2022+7%2023: $23.9B$23.9B2023−10%2024: $23.9B$23.9B2024−0%2025: $24.6B$24.6B2025+3%
Gross profit1112131410$14.5B in 2025+45% since 2019
0$5.0B$10.0B$15.0B$20.0B2019: $10.0B$10.0B20192020: $12.5B$12.5B2020+25%2021: $15.2B$15.2B2021+22%2022: $16.2B$16.2B2022+6%2023: $14.0B$14.0B2023−13%2024: $14.2B$14.2B2024+1%2025: $14.5B$14.5B2025+2%
Operating income1112131410$4.7B in 2025+43% since 2019
0$2.0B$4.0B$6.0B$8.0B2019: $3.3B$3.3B20192020: $4.2B$4.2B2020+29%2021: $6.4B$6.4B2021+51%2022: $7.5B$7.5B2022+18%2023: $5.2B$5.2B2023−31%2024: $4.9B$4.9B2024−7%2025: $4.7B$4.7B2025−4%
Net income1112131410$3.6B in 2025+20% since 2019
0$2.0B$4.0B$6.0B$8.0B2019: $3.0B$3.0B20192020: $3.6B$3.6B2020+21%2021: $6.4B$6.4B2021+76%2022: $7.2B$7.2B2022+12%2023: $4.8B$4.8B2023−34%2024: $3.9B$3.9B2024−18%2025: $3.6B$3.6B2025−7%

Every line of the income statement as filed: the last 3 fiscal years, latest first.10

Period ending2025-12-312024-12-312023-12-31
Sales$24.6B$23.9B$23.9B
Cost of sales-$10.0B-$9.7B-$9.9B
Gross profit$14.5B$14.2B$14.0B
Selling, general and administrative expenses-$8.2B-$7.8B-$7.3B
Research and development expenses-$1.6B-$1.6B-$1.5B
Operating profit$4.7B$4.9B$5.2B
Other income (expense), net-$222.0M-$56.0M-$175.0M
Interest expense-$265.0M-$278.0M-$286.0M
Interest income$30.0M$117.0M$303.0M
Earnings from continuing operations before income taxes$4.2B$4.6B$5.0B
Income taxes-$633.0M-$747.0M-$823.0M
Net earnings from continuing operations$3.6B$3.9B$4.2B
Earnings from discontinued operations, net of income taxes$14.0M$0$543.0M
Net earnings$3.6B$3.9B$4.8B
Mandatory convertible preferred stock dividends$0$0-$21.0M
Net earnings attributable to common stockholders$3.6B$3.9B$4.7B
Net earnings per common share from continuing operations, basic (in usd per share)$5$5$6
Net earnings per common share from continuing operations, diluted (in usd per share)$5$5$6
Net earnings per common share from discontinued operations, basic (in usd per share)$0$0$1
Net earnings per common share from discontinued operations, diluted (in usd per share)$0$0$1
Net earnings per common share, basic (in usd per share)$5.07$5.33$6.44
Net earnings per common share, diluted (in usd per share)$5.05$5.29$6.38
Basic (in shares)712.7M shares731.0M shares736.5M shares
Diluted (in shares)716.1M shares737.2M shares743.1M shares

Compare Danaher Corporation with another company

Corporate structure

Danaher Corporation sits at the top of its group. 146 entities, 28 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Danaher Corporation

  • VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on Danaher Corporation, latest Apr 29, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on Danaher Corporation, latest Mar 26, 2026 (5 filings since Feb 9, 2022)
  • BlackRock Filed SC 13G/A on Danaher Corporation, latest Jan 26, 2024 (4 filings since Feb 8, 2022)
  • Mitchell Rales Filed SC 13D/A on Danaher Corporation, latest Nov 2, 2021
  • Danaher Corporation Washington, the District of Columbia, United States
    • Danaher (China) Subsidiary · Shanghai, People's Republic of China
    • Nobel Biocare Subsidiary · Kloten, Switzerland
    • Teletrac Subsidiary · Santa Ana, California, United States
    • IsoPlexis Corp Stake · Branford, Connecticut
    • Telesis Bio Inc. Stake · San Diego, California, United States
    • AB Sciex Finance B.V. Subsidiary · Netherlands
    • AB Sciex LLC Subsidiary · Delaware, United States
    • Abcam Inc. Subsidiary · Massachusetts, United States
    • Abcam Trading (Shanghai) Co., Ltd Subsidiary · China
    • Aldevron LLC Subsidiary · North Dakota, United States
    • Aldevron Madison LLC Subsidiary · North Dakota, United States
    • BC Distribution B.V. Subsidiary · Netherlands
    • Beckman Coulter Biomedical GmbH Subsidiary · Germany
    • Beckman Coulter Biotechnology (Suzhou) Co., Ltd. Subsidiary · China
    • Beckman Coulter Canada LP Subsidiary · Canada
    • Beckman Coulter Commercial Enterprise (China) Co., Ltd. Subsidiary · China
    • Beckman Coulter France S.A.S. Subsidiary · France
    • Beckman Coulter Genomics Inc. Subsidiary · Delaware, United States
    • Beckman Coulter GmbH Subsidiary · Germany
    • Beckman Coulter Hong Kong Limited Subsidiary · Hong Kong
    • BECKMAN COULTER INDIA PRIVATE LIMITED Subsidiary · Mumbai, India
    • Beckman Coulter International S.A. Subsidiary · Switzerland
    • Beckman Coulter International Trading (Shanghai) Co., Ltd. Subsidiary · China
    • Beckman Coulter Ireland Inc. Subsidiary · Ireland
    • Beckman Coulter K.K. Subsidiary · Japan
    • and 119 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (2 companies). Each entity in the chart links to its source.

What it owns

What Danaher Corporation reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$10.3B10 Dec 31, 2025$9.1B10 Dec 31, 2024+13.3%
Accumulated depreciation$4.8B10 Dec 31, 2025$4.1B10 Dec 31, 2024+16.2%
Property and equipment, net$5.5B10 Dec 31, 2025$5.0B10 Dec 31, 2024+10.8%
Operating-lease assets (leased space)$1.2B10 Dec 31, 2025$1.1B10 Dec 31, 2024+12.0%

Investments

ItemLatestA year beforeChange
Debt securities available for sale$014 Dec 31, 2024$5.0M14 Dec 31, 2023−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$43.2B10 Dec 31, 2025$40.5B10 Dec 31, 2024+6.6%
Intangible assets, net (excluding goodwill)$17.8B10 Dec 31, 2025$18.6B10 Dec 31, 2024−4.0%
Finite-lived intangibles, gross$26.7B10 Dec 31, 2025$24.8B10 Dec 31, 2024+8.0%
Accumulated amortization$11.8B10 Dec 31, 2025$9.4B10 Dec 31, 2024+25.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$2.5B10 Dec 31, 2025$2.3B10 Dec 31, 2024+6.8%
Raw materials$733.0M10 Dec 31, 2025$720.0M10 Dec 31, 2024+1.8%
Work in process$469.0M10 Dec 31, 2025$465.0M10 Dec 31, 2024+0.9%
Finished goods$1.3B10 Dec 31, 2025$1.1B10 Dec 31, 2024+12.4%

Properties, in its own words

As of December 31, 2025, the Company had facilities in approximately 50 countries, including approximately 194 significant administrative, sales, R&D, manufacturing and distribution facilities. 77 of these facilities are located in the United States in over 20 states and 117 are located outside the United States, primarily in Europe, and to a lesser extent in Asia, Australia, Canada and South America. Refer to the accompanying Consolidated Financial Statements included in this Annual Report for additional information with respect to the Company’s lease commitments.

Item 2 of the 10-K filed Feb 24, 2026.20

The story

Founded by Mitchell Rales and Steven Rales in 1981.1

Early years

The company's origins go back to DMG, Inc., a Massachusetts real estate investment trust organized in 1969. In 1978, DMG, Inc. was reorganized as a Florida corporation and changed its name to Diversified Mortgage Investors, Inc. In 1983, the Stephen M. Rales and Mitchell P. Rales invested in the company, which at that time was invested in retirement home developments, they then replaced the existing management in a bitter proxy battle.

In 1984, the company adopted the name Danaher and reincorporated under the Delaware General Corporation Law. The name came from a river in Montana.

In 1985, the Rales brothers offered $400 million in a hostile bid for Scott Fetzer Company but lost out to Berkshire Hathaway.

In June 1986, Danaher acquired Chicago Pneumatic in a hostile takeover, offering $60.8 million for the 32% of the company not already owned. The company had merged in July 1984 with a sister company, the Jacobs Manufacturing Co., and had purchased Matco Tools in April 1981.

In June 1987, Danaher sold Chicago Pneumatic while retaining Jacobs, including its Matco Tools Division. Jacobs' name was changed to Matco Tools Corp. In November 1991, the other divisions within Jacobs were established as separate operating companies. In January 1993, Danaher formed NMTC, Inc., which acquired a substantial portion of the assets of MTC, including the existing distributorship agreements of MTC.

In 1986, Danaher added Qualitrol to its instrumentation unit, including Gilbarco Veeder-Root's underground fuel storage sensors, Dynapar's motion sensors, and pressure measurement and temperature measurement instruments used on the electrical transformer industry.

1990–2000

In 1990, Danaher acquired Easco Hand Tools Inc. Danaher was selected as exclusive supplier of hand tools for Sears. In 1994, Danaher acquired Armstrong Tools, the makers of tool brands Armstrong, Allen, and others.

In 1995, Danaher acquired Hengstler GmbH, a manufacturer of counters, printers, relays, and high-precision rotational sensors. Hengstler was Danaher's first acquisition headquartered outside the United States.

Read the full text

In 1999, the company acquired Hach Company, involved in water and wastewater—and analytics, for $325 million.

2001–2010

In 2000, H. Lawrence Culp Jr. was named CEO of Danaher; he had joined the company in 1990.

Danaher acquired Trojan Technologies, an environmental engineering firm, in 2004.

Danaher also acquired UK-based West Instruments, which provides control and measurement instrumentation and services for the global industrial and process markets.

Danaher announced its agreement to acquire the Gendex division from DENTSPLY International on

December 11, 2003, with the acquisition closing in early 2004, integrating this dental imaging company into Danaher's growing dental portfolio.

PMA, a German manufacturer of control and measurement instrumentation, was acquired in April 2005.

In July 2005, Danaher acquired Leica Microsystems, which manufactures products for applications requiring microscopic imaging, measurement and analysis and offers management systems for biotechnology and medicine, as well as the science of raw materials and industrial quality assurance.

In early 2007, Danaher acquired Vision Systems, which manufactures and markets automated instruments, antibodies and biochemical reagents for biopsy-based detection of cancer and infectious diseases, for $520 million.

In July 2007, Danaher acquired ChemTreat.

In November 2007, Danaher purchased Tektronix for US$2.85 billion.

In 2009, Danaher acquired the Analytical Technologies business unit of MDS, including a 50% interest in AB SCIEX, for US$650 million. In February 2010, Danaher acquired the remaining 50% ownership position in AB SCIEX from Life Technologies for US$450 million.

2011–2020

In 2011, Danaher acquired Beckman Coulter, which was divided into a diagnostics segment and a life sciences segment.

In January 2012, Danaher sold Accu-sort to Datalogic.

In December 2012, Danaher acquired Navman Wireless, a provider of on-demand fleet and asset management technology.

In February 2013, Danaher and Cooper Industries sold their joint venture, Apex Tool Group, to Bain Capital for $1.6 billion.

In September 2014, Danaher acquired Nobel Biocare for $2.2 billion.

Effective March 1, 2015, H. Lawrence Culp Jr. resigned as CEO of Danaher.

In July 2015, Danaher combined its communications unit with NetScout Systems.

In August 2015, Danaher acquired Pall Corporation for $13.8 billion.

In June 2016, Danaher completed the corporate spin-off of Fortive, which included Matco and AMMCO-COATS. In September of the same year, the company announced it would acquire Cepheid for $4 billion including debt.

In October 2016, Danaher acquired Phenomenex for $700 million to expand in life sciences.

In October 2017, Danaher announced the acquisition of scientific informatics company ID Business Solutions Ltd. (IDBS). IDBS became part of Danaher's Life Sciences platform.

In March 2018, Danaher acquired Integrated DNA Technologies for an estimated $1.9 billion.

In July 2018, Danaher announced its intention to spin off its Dental segment into a public company, later named Envista Holdings Corporation. The corporate spin-off was completed in December 2019.

In March 2020, Integrated DNA Technologies, a subsidiary of the company, manufactured components for COVID-19 testing.

In March 2020, Danaher acquired the biopharma business of General Electric, a global provider of technologies and services related to the development, manufacture, and delivery of vaccines, diagnostics, and therapeutics to customers in organizations including academia, biotechnology, and drug manufacturing, for $21.4 billion and was rebranded as Cytiva. The GE deal raised monopoly concerns. The Federal Trade Commission conditionally approved the deal on the grounds that Danaher sold some biotechnology assets. In a second deal, Danaher's biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards businesses were sold to Sartorius AG for approximately $825 million. The Cytiva name is derived from 'cyto' meaning 'cell' in Greek, and 'iva' a Latin suffix meaning 'doing' and 'capable of'.

Effective September 2020, Tom Joyce retired as CEO of the company; he was replaced by Executive Vice President Rainer Blair.

2021–present

In June 2021, Precision Nanosystems was acquired by Cytiva.

In August 2021, Danaher acquired Aldevron, which produces mRNA and proteins used in mRNA vaccines, for $9.6 billion in cash.

In May 2023, Pall Corporation merged with Cytiva to create a new Biotechnology Group within Danaher; at that time Cytiva employed more than 16,000 associates in over 40 countries.

Also in September 2022, Danaher announced its intention to spin off its Environmental & Applied Solutions segment; in February 2023, it was named Veralto and the corporate spin-off was completed in September 2023. The division included Aquatic Informatics, ChemTreat, Esko, Hach Company, Linx, McCrometer, OTT HydroMet, Pantone, Sea-Bird Scientific, Trojan Technologies, Videojet, XOS, and X-Rite.

In December 2023, Danaher acquired Abcam for approximately $5.7 billion.

In June 2024, the Food and Drug Administration granted marketing approval to Danaher's Cepheid unit for a rapid test for hepatitis C. Using a blood sample from a fingertip, the rapid test detects the virus's RNA and delivers results in less than roughly an hour, as opposed to requiring a sample to be sent to a lab.

In August 2024, the company acquired GeneData. In February 2026, Danaher announced it would acquire Masimo for $10 billion.

From Wikipedia’s article on Danaher Corporation, shared under CC BY-SA 4.0.8

Leadership

Who has led Danaher Corporation, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (44)

Products and brands

Life sciences

Abcam

Beckman Coulter - Life Sciences

Cytiva

Integrated DNA Technologies

Read the full text

Leica Microsystems

Molecular Devices

Pall Corporation

SCIEX

Diagnostics

Beckman Coulter - Diagnostics

Cepheid

Leica Biosystems

Radiometer

From Wikipedia’s article on Danaher Corporation, shared under CC BY-SA 4.0.8

Subsidiaries and ownership

Owners

Subsidiaries

Subsidiaries (Exhibit 21)

  • AB Sciex Finance B.V. Netherlands9
  • AB Sciex LLC Delaware9
  • AB Sciex LP Canada9
  • AB Sciex Pte. Ltd. Singapore9
  • Abcam Inc. Massachusetts9
  • Abcam Limited United Kingdom9
  • Abcam Trading (Shanghai) Co., Ltd China9
  • Aldevron LLC North Dakota9
  • Aldevron Madison LLC North Dakota9
  • BC Distribution B.V. Netherlands9
  • Beckman Coulter Biomedical GmbH Germany9
  • Beckman Coulter Biotechnology (Suzhou) Co., Ltd. China9
  • Beckman Coulter Canada LP Canada9
  • Beckman Coulter Commercial Enterprise (China) Co., Ltd. China9
  • Beckman Coulter France S.A.S. France9
  • Beckman Coulter Genomics Inc. Delaware9
  • Beckman Coulter GmbH Germany9
  • Beckman Coulter Hong Kong Limited Hong Kong9
  • Beckman Coulter India Private Limited India9
  • Beckman Coulter International S.A. Switzerland9
  • Beckman Coulter International Trading (Shanghai) Co., Ltd. China9
  • Beckman Coulter Ireland Inc. Ireland9
  • Beckman Coulter K.K. Japan9
  • Beckman Coulter Korea Ltd. Korea, Republic of9
All 137 listed subsidiaries
  • Beckman Coulter Laboratory Systems (Suzhou) Co. Ltd. China9
  • Beckman Coulter Limited Liability Company Russian Federation9
  • Beckman Coulter Mishima K.K. Japan9
  • Beckman Coulter Saudi Arabia Co. Ltd. Saudi Arabia9
  • Beckman Coulter Srl Italy9
  • Beckman Coulter Taiwan Inc. California9
  • Beckman Coulter United Kingdom Limited United Kingdom9
  • Beckman Coulter, S.L.U. Spain9
  • Biacore International AB Sweden9
  • BioVision, Inc California9
  • Biosafe SA Switzerland9
  • CEVEC Pharmaceuticals GmbH Germany9
  • Cepheid California9
  • Cepheid AB Sweden9
  • Cepheid Europe SAS France9
  • Cepheid GmbH Germany9
  • Cepheid HBDC SAS France9
  • Cytiva Belgium BV Belgium9
  • Cytiva BioProcess R&D AB Sweden9
  • Cytiva Biotechnology (Guangzhou) Co., Ltd. China9
  • Cytiva Denmark Manufacturing ApS Denmark9
  • Cytiva Europe GmbH Germany9
  • Cytiva Ireland Limited Ireland9
  • Cytiva Italy SRL Italy9
  • Cytiva Sweden AB Sweden9
  • Cytiva US LLC Delaware9
  • Cytiva do Brasil Comércio e Serviços para Biotecnologia Ltda. Brazil9
  • DH Europe Finance II Sarl Luxembourg9
  • DH Europe Finance S.à.r.l. Luxembourg9
  • DH Holdings Corp. Delaware9
  • DH Holdings Germany LLC Delaware9
  • DH Japan Finance S.à.r.l. Luxembourg9
  • DH Life Sciences LLC Delaware9
  • DH Technologies Development Pte Ltd. Singapore9
  • DH UK Partners United Kingdom9
  • DHCDAN Holding ApS Denmark9
  • DHRAT GmbH Austria9
  • DTIL Ireland Holdings Ltd. Ireland9
  • Danaher Business System IP Holdings LLC Delaware9
  • Danaher Medical ApS Denmark9
  • Devicor Medical Products, Inc. Delaware9
  • Epitomics Inc. Delaware9
  • FJ 900, Inc. Delaware9
  • GLS Sweden Holdings AB Sweden9
  • Genedata AG Switzerland9
  • Gilzoni Holdings Italia S.R.L. Italy9
  • Global Life Sciences Solutions Australia Pty Ltd Australia9
  • Global Life Sciences Solutions Canada ULC Canada9
  • Global Life Sciences Solutions Germany GmbH Germany9
  • Global Life Sciences Solutions Korea Limited Korea, Republic of9
  • Global Life Sciences Solutions Manufacturing UK Ltd United Kingdom9
  • Global Life Sciences Solutions Operations UK Ltd. United Kingdom9
  • Global Life Sciences Solutions Singapore Pte. Ltd. Singapore9
  • Global Life Sciences Solutions USA LLC Delaware9
  • Global Life Sciences Technologies (Shanghai) Co., Ltd. China9
  • Global Life Sciences Technologies Japan K.K. Japan9
  • HemoCue AB Sweden9
  • HyClone Laboratories, LLC Delaware9
  • Hybritech Incorporated California9
  • Hyclone Life Sciences Solutions India Private Limited India9
  • ID Business Solutions Limited United Kingdom9
  • InSilixa, Inc. Delaware9
  • Intabio, LLC Delaware9
  • Integrated DNA Technologies, B.V. Belgium9
  • Iris International, Inc. Delaware9
  • Labcyte Inc. Delaware9
  • Launchchange Operations Limited United Kingdom9
  • Leica Biosystems Imaging, Inc. Delaware9
  • Leica Biosystems Melbourne Pty Ltd Australia9
  • Leica Biosystems Newcastle Limited United Kingdom9
  • Leica Biosystems Richmond, Inc. Illinois9
  • Leica Instruments (Singapore) Pte Limited Singapore9
  • Leica Microsystems (UK) Limited United Kingdom9
  • Leica Microsystems CMS GmbH Germany9
  • Leica Microsystems IR GmbH Germany9
  • Leica Microsystems Inc. Delaware9
  • Leica Microsystems Ltd. Shanghai China9
  • Leica Mikrosysteme GmbH Austria9
  • Leica Mikrosysteme Vertrieb GmbH Germany9
  • Life Sciences IP Holdings Corp Delaware9
  • Molecular Devices, LLC Delaware9
  • Nihon Pall Ltd. Japan9
  • Nihon Pall Manufacturing Limited Japan9
  • Pall (Canada) ULC Canada9
  • Pall (China) Co., Ltd. China9
  • Pall (Schweiz) GmbH Switzerland9
  • Pall Aeropower Corporation Delaware9
  • Pall Arabia for Trading Saudi Arabia9
  • Pall Asia International Ltd. Hong Kong9
  • Pall Austria Filter Ges.m.b.h. Austria9
  • Pall Biotech (Beijing) Co., Ltd. China9
  • Pall Europe Limited United Kingdom9
  • Pall Filtration Pte Ltd Singapore9
  • Pall France SAS France9
  • Pall GmbH Germany9
  • Pall International SARL Switzerland9
  • Pall Korea Ltd Korea, Republic of9
  • Pall Life Sciences Belgium BV Belgium9
  • Pall Life Sciences Puerto Rico, LLC Puerto Rico9
  • Pall Manufacturing UK Limited United Kingdom9
  • Pall Medistad B.V. Netherlands9
  • Pall SAS France9
  • Pall Sarl Switzerland9
  • Pall Singapore Taiwan Branch Holding Company Pte Ltd Taiwan9
  • Pall Technology UK Limited United Kingdom9
  • Phenomenex, Inc. California9
  • Radiometer Medical ApS Denmark9
  • Radiometer Solutions Sp. z o.o. Poland9
  • Radiometer Turku Oy Finland9
  • Shanghai AB Sciex Analytical Instrument Trading Co., Ltd. China9
  • TGR BioSciences Pty Limited Australia9
  • VR Finance Company United Kingdom9
  • Vanrx Pharmasystems Inc. Canada9

From Wikidata.1 The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Acquisitions

  1. Mar 19, 2018Integrated DNA Technologies became a subsidiary1
  2. Oct 11, 2016Acquired Phenomenex1
  3. Aug 31, 2015Acquired Pall Corporation1
  4. 2012Beckman Coulter became a subsidiary1
  5. 2004Acquired KaVo Dental1

Timeline

  1. Oct 13, 20268-K Executive or director change; Other events72
  2. Aug 3, 20268-K Executive or director change; Regulation FD disclosure; Other events73
  3. Jul 21, 20268-K Results of operations74
  4. Jun 3, 20268-K New debt or obligation; Other events75
  5. May 7, 20268-K Executive or director change; Shareholder vote76
  6. Apr 29, 20268-K Entered a material agreement; Other events77
  7. Apr 21, 20268-K Results of operations78
  8. Apr 17, 20268-K Entered a material agreement; New debt or obligation79
  9. Feb 17, 20268-K Other events80
  10. Feb 10, 20268-K Executive or director change81
  11. Jan 28, 20268-K Results of operations82
  12. Jan 12, 20268-K Results of operations83
  13. Nov 17, 2020New chief executive Rainer Blair becomes CEO21
  14. May 6, 2014New chief executive Thomas Patrick Joyce Jr. becomes CEO22
  15. Jan 3, 2006New chief executive H. Lawrence Culp Jr. becomes CEO23
  16. 1981Founded Founded1

Calendar

Coming up

  1. Oct 21, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $1.89 a share, on Oct 21, 2025.84

When it reported results

  1. Jul 21, 2026Reported quarterly or annual results74
  2. Apr 21, 2026Reported quarterly or annual results78
  3. Jan 28, 2026Reported quarterly or annual results82
  4. Jan 12, 2026Reported quarterly or annual results83
  5. Oct 21, 2025Reported quarterly or annual results85
  6. Jul 22, 2025Reported quarterly or annual results86
  7. Apr 22, 2025Reported quarterly or annual results87
  8. Jan 29, 2025Reported quarterly or annual results88

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

766 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 57 major events, 559 insider forms, 11 large holders, 119 other. The latest 20:

  1. Oct 14, 20264 EDGAR
  2. Oct 14, 20264 EDGAR
  3. Oct 13, 20268-K EDGAR
  4. Oct 2, 20263 EDGAR
  5. Oct 2, 20263 EDGAR
  6. Sep 30, 202625-NSE EDGAR
  7. Aug 24, 20264 EDGAR
  8. Aug 21, 2026144 EDGAR
  9. Aug 6, 20264 EDGAR
  10. Aug 6, 20264 EDGAR
  11. Aug 6, 20264 EDGAR
  12. Aug 6, 20264 EDGAR
  13. Aug 6, 20264 EDGAR
  14. Aug 6, 20264 EDGAR
  15. Aug 6, 20264 EDGAR
  16. Aug 6, 20264 EDGAR
  17. Aug 6, 20264 EDGAR
  18. Aug 4, 20264 EDGAR
  19. Aug 4, 20264 EDGAR
  20. Aug 4, 20264 EDGAR

The 766 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

69 open-market trades by officers, directors and large owners since October 2021: 1 buys and 68 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 21, 2026Blair RainerPresident & CEOSale58,255$218.63$12.7MForm 4
May 1, 2026SPOON ALAN GDirectorSale1,358$174.67$237.2KForm 4
Feb 19, 2026Milosevich Gregory MExecutive Vice PresidentSale1,320$208.01$274.6KForm 4
Nov 25, 2025RALES MITCHELL PChairman of Exec. CommitteeSale40,625$230.38$9.4MForm 4
Nov 18, 2025List TeriDirectorSale3,298$226.50$747.0KForm 4
Nov 12, 2025RALES MITCHELL PChairman of Exec. CommitteeSale437,000$218.69$95.6MForm 4
Nov 12, 2025Ellis Brian WSenior Vice PresidentSale21,776$219.22$4.8MForm 4
Nov 11, 2025McGrew MatthewExecutive Vice PresidentSale16,172$214.62$3.5MForm 4
Nov 10, 2025Couchara GeorgeannSVP, Human ResourcesSale5,174$210.41$1.1MForm 4
Oct 31, 2025RALES MITCHELL PChairman of Exec. CommitteeSale600,000$216.06$129.6MForm 4
Aug 22, 2025List TeriDirectorSale2,778$211.06$586.3KForm 4
May 12, 2025RALES STEVEN MChairmanSale1,250,000$196.74$245.9MForm 4
Apr 30, 2025Riley Christopher PaulExecutive Vice PresidentSale15,805$198.00$3.1MForm 4
Feb 7, 2025SPOON ALAN GDirectorSale550$206.46$113.6KForm 4
Jan 30, 2025Ellis Brian WSenior Vice PresidentSale5,700$224.13$1.3MForm 4
Nov 26, 2024Raskas DanielSVP - Corporate DevelopmentSale26,318$236.59$6.2MForm 4
Nov 25, 2024Raskas DanielSVP - Corporate DevelopmentSale8,370$238.00$2.0MForm 4
Aug 26, 2024Couchara GeorgeannSVP, Human ResourcesSale952$268.37$255.5KForm 4
Aug 1, 2024FILLER LINDADirectorSale3,928$279.50$1.1MForm 4
Aug 1, 2024McGrew MatthewExecutive Vice PresidentSale16,172$279.84$4.5MForm 4

All 69 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

Danaher Corporation has told the SEC it owns more than 5% of 2 companies, latest first (Schedules 13D and 13G).

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Rainer M. BlairPresident and CEO$1.4M$23.8M95
2025Julie Sawyer MontgomeryExecutive Vice President$848.0K$11.3M95
2025Christopher P. RileyExecutive Vice President$848.0K$11.3M95
2025Matthew R. McGrewExecutive Vice President and CFO$1.0M$8.0M95
2025Jose-Carlos Gutierrez-RamosSenior Vice President and Chief Science Officer$888.5K$6.2M95
2024Rainer M. BlairPresident and CEO$1.4M$22.1M95
2024Jose-Carlos Gutierrez-RamosSenior Vice President and Chief Science Officer$862.6K$7.5M95
2024Matthew R. McGrewExecutive Vice President and CFO$990.5K$7.5M95
2023Rainer M. BlairPresident and CEO$1.3M$20.9M95
2023Matthew R. McGrewExecutive Vice President and CFO$966.3K$7.5M95
2023Jose-Carlos Gutierrez-RamosSenior Vice President and Chief Science Officer$784.2K$7.2M95

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.55,084,630$10.5B0.2%+3,444,011
Vanguard Capital Management LLC41,377,076$7.9B0.2%+249,266
Fmr LLC29,540,895$5.6B0.2%+7,006,566
State Street Corp28,456,019$5.4B0.2%+561,838
Wellington Management Group Llp16,316,834$3.1B0.5%+1,542,310
Capital International Investors15,504,420$3.0B0.6%+1,489,707
Geode Capital Management, LLC14,280,335$2.7B0.1%+134,577
Vanguard Portfolio Management LLC14,205,213$2.7B0.1%+250,508
Jpmorgan Chase & Co12,185,400$2.3B0.1%−4,732,249
Morgan Stanley11,348,958$2.2B0.1%+139,718
Capital Research Global Investors10,818,030$2.1B0.3%+1,920,257
Norges Bank9,537,906$1.8B0.2%New
Eagle Capital Management LLC9,361,490$1.8B5.4%+2,786,331
Jupiter Topco LLC7,645,709$1.5B0.6%New
Northern Trust Corp6,925,441$1.3B0.2%−155,460
Generation Investment Management Llp6,761,596$1.3B12.5%−512,799
Goldman Sachs Group Inc5,364,861$1.0B0.1%+755,573
Nuveen, LLC5,242,679$998.6M0.2%−92,076
Bank Of America Corp /de/5,217,586$993.8M0.1%−1,034,530
Arrowstreet Capital, Limited Partnership5,163,059$983.5M0.4%+1,523,429
Charles Schwab Investment Management Inc5,140,868$979.2M0.1%+405,970
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC5,012,228$954.7M0.2%−213,633
Fisher Asset Management, LLC4,484,774$854.3M0.3%−121,660
Legal & General Group Plc4,205,461$801.1M0.2%−329,564
Massachusetts Financial Services Co /ma/3,878,641$762.2M0.2%−287,128

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

53 trades disclosed by members of Congress, the latest 25. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Sep 2, 2026Kevin HernRepublican, HousePartial sale$1,001 - $15,000−8.2%Report
Aug 31, 2026Kevin HernRepublican, HouseSale$15,001 - $50,000−6.6%Report
Mar 27, 2026Alan ArmstrongRepublican, SenateBuy$1,001 - $15,000+4.5%Report
Dec 18, 2025Julie JohnsonDemocratic, HouseSale$1,001 - $15,000+12.0%Report
Nov 13, 2025Julie JohnsonDemocratic, HousePartial sale$1,001 - $15,000+11.3%Report
Oct 7, 2025Julie JohnsonDemocratic, HouseBuy$1,001 - $15,000−5.6%Report
Sep 25, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000−8.9%Report
Sep 3, 2025Thomas H. Kean, Jr.Republican, HouseBuy$1,001 - $15,000−5.1%Report
Aug 28, 2025Sheldon WhitehouseDemocratic, SenateSale$1,001 - $15,000+7.4%Report
Jul 22, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000−2.1%Report
Jun 12, 2025Pete SessionsRepublican, HouseSale$50,001 - $100,000+16.2%Report
Jun 11, 2025Thomas H. Kean, Jr.Republican, HouseBuy$1,001 - $15,000−16.5%Report
May 15, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$1,001 - $15,000+10.8%Report
May 12, 2025Jefferson ShreveRepublican, HouseSale$15,001 - $50,000+18.3%Report
Apr 28, 2025Julia LetlowRepublican, HouseBuy$1,001 - $15,000−23.2%Report
Apr 21, 2025Bruce WestermanRepublican, HouseSale$1,001 - $15,000+26.4%Report
Apr 11, 2025Dan NewhouseRepublican, HousePartial sale$1,001 - $15,000+23.2%Report
Apr 8, 2025Robert P. Bresnahan, Jr.Republican, HouseBuy$15,001 - $50,000−24.3%Report
Apr 7, 2025Jefferson ShreveRepublican, HouseSale$15,001 - $50,000+26.2%Report
Mar 27, 2025Greg LandsmanDemocratic, HouseSale$1,001 - $15,000+27.1%Report
Feb 26, 2025Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+20.5%Report
Feb 25, 2025Robert P. Bresnahan, Jr.Republican, HouseSale$15,001 - $50,000+21.0%Report
Feb 13, 2025Markwayne Mullin, SenateSale$15,001 - $50,000+14.1%Report
Jan 15, 2025Julie JohnsonDemocratic, HouseSale$1,001 - $15,000+34.0%Report
Oct 29, 2024Val T. HoyleDemocratic, HouseBuy$1,001 - $15,000−38.3%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Danaher Corporation is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARDANAHER CORP /DE/2
  • CIK0000313616
  • Employer ID (EIN)59-199554820
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company20
  • Incorporated inDelaware20
  • Fiscal year endsDecember 312
  • Industry code (SIC)3823 Industrial Instruments For Measurement, Display, and Control2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address2200 Pennsylvania Ave. N.W., Suite 800W, Washington, DC 20037-17012
  • Phone20282808502
  • Shares outstanding702,986,054 as of Jul 16, 202617
  • Public float$125.9B as of Jun 30, 202520
  • AuditorErnst & Young LLP, Tysons, Virginia PCAOB ID 42; it also attests to the company’s internal control over financial reporting20
  • On EDGAR sinceFeb 14, 19942
  • Filings3,712 in all: 4 (2,315), 8-K (285), 5 (104), 425 (101), 10-Q (98), SC 13G/A (58), 144 (55), SC TO-T/A (48)2
    All 68 form types

    3 (44), 11-K (39), 4/A (37), SC 14D1/A (34), 424B3 (33), DEF 14A (33), 424B5 (32), 10-K (30), SC 13D/A (29), S-8 (25), SC 13D (18), SC TO-C (18), DEFA14A (16), FWP (16), SC 13G (16), ARS (15), DFAN14A (15), UPLOAD (15), CORRESP (14), SD (13), IRANNOTICE (11), 25-NSE (10), S-3 (9), SC TO-T (9), 424B2 (8), PRE 14A (8), S-3ASR (8), 8-A12B (7), 8-K/A (7), S-3/A (7), SC TO-I/A (7), NO ACT (6), 10-K/A (5), CERT (5), 10-Q/A (4), SC 14D1 (4), 10-K405 (3), PREC14A (3), PX14A6G (3), S-8 POS (3), 3/A (2), 424B4 (2), POS AM (2), POSASR (2), PRES14A (2), S-3DPOS (2), S-4 (2), SC TO-I (2), SCHEDULE 13G/A (2), 144/A (1), 25 (1), 305B2 (1), 424B7 (1), CERTNYS (1), D (1), DEFN14A (1), PREN14A (1), RW (1), S-4/A (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Feb 24, 2026
    Quarterly report (10-Q) Jul 21, 2026
    Proxy statement (DEF 14A) Mar 25, 2026
    Latest 8-K (8-K) Oct 13, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, $0.01 par valueDHRNew York Stock Exchange
0.200% Senior Notes due 2026DHR/26New York Stock Exchange
2.100% Senior Notes due 2026DHR 26New York Stock Exchange
1.200% Senior Notes due 2027DHR/27New York Stock Exchange
0.450% Senior Notes due 2028DHR/28New York Stock Exchange
2.500% Senior Notes due 2030DHR 30New York Stock Exchange
0.750% Senior Notes due 2031DHR/31New York Stock Exchange
1.350% Senior Notes due 2039DHR/39New York Stock Exchange
1.800% Senior Notes due 2049DHR/49New York Stock Exchange

From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).20

Risk factors and legal proceedings

The risks Danaher Corporation names in Item 1A of its 10-K filed Feb 24, 2026: 42 risks under these headings, as written.20

  • Business and Strategic Risks
  • Conditions in the global economy, the particular markets we serve and the financial markets can adversely affect our business and financial statements.
  • We face intense competition and if we are unable to compete effectively, we may experience decreased demand and decreased market share. Even if we compete effectively, we may be required to reduce the prices we charge.
  • Our growth depends in part on the timely development and commercialization, and customer acceptance, of new and enhanced products and services based on technological innovation.
  • The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes in an effort to reduce (and increase the predictability of) costs, which can adversely affect our business and financial statements.
  • Non-U.S. economic, political, legal, compliance, social and business factors can negatively affect our business and financial statements.
  • Our growth can suffer if the markets into which we sell our products and services decline, do not grow as anticipated or experience cyclicality.
  • Uncertainties with respect to the development, deployment, and use of AI in our business and products may result in harm to our business and reputation.
  • Global health crises, pandemics, epidemics or other outbreaks can adversely impact certain elements of our business and financial statements.
  • Certain of our businesses rely on relationships with business partners and other third-parties for development, supply and/or marketing of certain products, potential products and technologies, and such business partners or other third-parties could fail to perform sufficiently.
  • Acquisition, Divestiture and Investment Risks
  • Failing to consummate acquisitions at our historical rate and at appropriate prices, and to make appropriate investments that support our long-term strategy, can negatively impact our business.
The other 32 risks
  • Our acquisition of businesses, investments, joint ventures and other strategic relationships can negatively impact our business and financial statements.
  • The indemnification provisions of acquisition agreements by which we have acquired companies may not fully protect us and as a result we may face unexpected liabilities.
  • Divestitures or other dispositions could negatively impact our business, and contingent liabilities from businesses that we or our predecessors have disposed of could adversely affect our business and financial statements.
  • We could incur significant liability if our dispositions of any of Fortive Corporation, Envista Holdings Corporation or Veralto Corporation is determined to be a taxable transaction.
  • Operational Risks
  • Significant disruptions in, or breaches in security of, our IT systems or data or violation of data privacy laws can adversely affect our business and financial statements.
  • Defects and unanticipated use or inadequate disclosure with respect to our products or services, or allegations thereof, can adversely affect our business and financial statements.
  • If we suffer loss to our facilities, supply chains, distribution systems or IT systems due to catastrophe or other events, our operations could be seriously harmed.
  • Climate change, legal or regulatory measures to address climate change and other sustainability topics and any inability on our part to address the range of stakeholder expectations relating to climate change and other sustainability topics may negatively affect us.
  • The manufacture of many of our products is a highly exacting and complex process, and if we directly or indirectly encounter problems manufacturing products, our business and financial statements could suffer.
  • Our financial results are subject to fluctuations in the cost and availability of the supplies that we use in, and the labor we need for, our operations.
  • Adverse changes in our relationships with, or the financial condition, performance, purchasing patterns or inventory levels of, key distributors and other channel partners can adversely affect our business and financial statements.
  • Our success depends on our ability to recruit, retain and motivate talented employees.
  • Intellectual Property Risks
  • If we are unable to adequately protect our intellectual property, or if third-parties infringe our intellectual property rights, we may suffer competitive injury or expend significant resources enforcing our rights. These risks are particularly pronounced in countries in which we do business that do not have levels of protection of intellectual property comparable to the United States.
  • Third-parties from time to time claim that we are infringing or misappropriating their intellectual property rights and we could suffer significant litigation expenses, losses or licensing expenses or be prevented from selling products or services.
  • The U.S. government has certain rights with respect to incremental production capacity attributable to, and/or the intellectual property we have developed, using government financing. In addition, in times of national emergency the U.S. government could control our allocation of manufacturing capacity.
  • Financial and Tax Risks
  • From time to time our outstanding debt has increased significantly as a result of acquisitions, and we expect to incur additional debt in the future. Our existing and future indebtedness may limit our operations and our use of our cash flow and negatively impact our credit ratings; and any failure to comply with the covenants that apply to our indebtedness could adversely affect our business and financial statements.
  • We may be required to recognize impairment charges for our goodwill and other intangible assets.
  • Foreign currency exchange rates can adversely affect our financial statements.
  • Changes in our tax rates or exposure to additional income tax liabilities or assessments can affect our profitability. In addition, audits by tax authorities can result in additional tax payments for prior periods.
  • Changes in tax law relating to multinational corporations could adversely affect our tax position.
  • Military conflicts (such as the conflicts between Russia and Ukraine and in the Middle East) can adversely affect our business and financial statements.
  • Legal, Regulatory, Compliance and Reputational Risks
  • Significant developments or changes in national laws or policies to protect or promote domestic interests and/or address foreign competition can have an adverse effect on our business and financial statements.
  • Our business and financial statements can be impaired by improper conduct by any of our employees, agents or business partners.
  • Our businesses are subject to extensive regulation; failure to comply with those regulations could adversely affect our business and financial statements.
  • We are subject to or otherwise responsible for a variety of litigation and other legal and regulatory proceedings in the course of our business that can adversely affect our business and financial statements.
  • Certain of our businesses are subject to extensive regulation by the FDA and by comparable agencies of other countries, as well as laws regulating fraud and abuse in the healthcare industry and the privacy and security of health information. Failure to comply with those regulations could adversely affect our business and financial statements.
  • Our products can be subject to human clinical trials, the results of which may be unexpected, or perceived as unfavorable by the market, and could adversely affect our business and financial statements.
  • Off-label marketing of our products could result in substantial penalties.
  • Certain modifications to our products may require new 510(k) clearances or other marketing authorizations and may require us to recall or cease marketing our products.
  • Our operations, products and services expose us to the risk of environmental, health and safety liabilities, costs and violations that could adversely affect our business and financial statements.
  • Changes in governmental regulations can reduce demand for our products or services or increase our expenses.
  • Exclusive forum provisions in our By-laws could limit our stockholders’ ability to choose their preferred judicial forum for disputes with us or our directors, officers or employees.

Legal proceedings

For information regarding legal proceedings, refer to Note 17 in the accompanying Consolidated Financial Statements included in this Annual Report.

Consistent with SEC Regulation S-K Item 103, we have elected to disclose those environmental proceedings (if any) with a governmental entity as a party where the Company reasonably believes such proceeding would result in monetary sanctions, exclusive of interest and costs, of $1 million or more.

The opening of Item 3, Legal Proceedings.20

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Yahoo FinanceDHR quote
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
    SEC EDGAROther events
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95